Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, April 1, 2024
[ Mon, Apr 01st 2024
] - WOPRAI
[ Mon, Apr 01st 2024
] - WOPRAI
Sun, March 31, 2024
[ Sun, Mar 31st 2024
] - WOPRAI
Thu, March 28, 2024
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
[ Thu, Mar 28th 2024
] - WOPRAI
Ed Arce Maintained (AKBA) at Strong Buy with Increased Target to $6 on, Mar 28th, 2024
Ed Arce of HC Wainwright & Co., Maintained "Akebia Therapeutics, Inc." (AKBA) at Strong Buy with Increased Target from $5 to $6 on, Mar 28th, 2024.
Ed has made no other calls on AKBA in the last 4 months.
There is 1 other peer that has a rating on AKBA. Out of the 1 peers that are also analyzing AKBA, 0 agree with Ed's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ed
- Julian Harrison of "BTIG" Initiated at Strong Buy and Held Target at $4 on, Wednesday, November 29th, 2023
